PortfoliosLab logoPortfoliosLab logo
CHRS vs. MLECW
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CHRS vs. MLECW - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Coherus BioSciences, Inc. (CHRS) and Moolec Science SA Warrant (MLECW). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CHRS achieves a 4.23% return, which is significantly lower than MLECW's 205.17% return.


CHRS

1D
0.00%
1M
-8.07%
YTD
4.23%
6M
5.71%
1Y
98.07%
3Y*
-28.15%
5Y*
-36.77%
10Y*
-20.84%

MLECW

1D
14.94%
1M
-11.50%
YTD
205.17%
6M
75.25%
1Y
5.36%
3Y*
-38.18%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

CHRS vs. MLECW - Yearly Performance Comparison


2026 (YTD)202520242023
CHRS
Coherus BioSciences, Inc.
4.23%2.90%-58.56%-57.95%
MLECW
Moolec Science SA Warrant
205.17%-77.17%15.45%-98.65%

Correlation

The correlation between CHRS and MLECW is -0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

-0.02

Correlation (3Y)
Calculated over the trailing 3-year period

-0.02

Correlation (All Time)
Calculated using the full available price history since Jan 3, 2023

-0.03

Fundamentals

Total Revenue (TTM)

CHRS:

$46.88M

MLECW:

$7.83M

Gross Profit (TTM)

CHRS:

$23.41M

MLECW:

-$639.50K

EBITDA (TTM)

CHRS:

-$162.15M

MLECW:

-$5.21M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CHRS vs. MLECW — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CHRS
CHRS Risk / Return Rank: 7575
Overall Rank
CHRS Sharpe Ratio Rank: 7777
Sharpe Ratio Rank
CHRS Sortino Ratio Rank: 7575
Sortino Ratio Rank
CHRS Omega Ratio Rank: 7272
Omega Ratio Rank
CHRS Calmar Ratio Rank: 7777
Calmar Ratio Rank
CHRS Martin Ratio Rank: 7272
Martin Ratio Rank

MLECW
MLECW Risk / Return Rank: 5959
Overall Rank
MLECW Sharpe Ratio Rank: 4343
Sharpe Ratio Rank
MLECW Sortino Ratio Rank: 8484
Sortino Ratio Rank
MLECW Omega Ratio Rank: 8282
Omega Ratio Rank
MLECW Calmar Ratio Rank: 4444
Calmar Ratio Rank
MLECW Martin Ratio Rank: 4343
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CHRS vs. MLECW - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Coherus BioSciences, Inc. (CHRS) and Moolec Science SA Warrant (MLECW). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CHRSMLECWDifference
Sharpe ratioReturn per unit of total volatility

+1.19

Sortino ratioReturn per unit of downside risk

-0.57

Omega ratioGain probability vs. loss probability

1.23

1.32

-0.09

Calmar ratioReturn relative to maximum drawdown

2.15

0.07

+2.08

Martin ratioReturn relative to average drawdown

4.08

0.11

+3.97

CHRS vs. MLECW - Sharpe Ratio Comparison

The current CHRS Sharpe Ratio is 1.21, which is higher than the MLECW Sharpe Ratio of 0.02. The chart below compares the historical Sharpe Ratios of CHRS and MLECW, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CHRS vs. MLECW - Drawdown Comparison

The maximum CHRS drawdown since its inception was -98.21%, roughly equal to the maximum MLECW drawdown of -99.71%. Use the drawdown chart below to compare losses from any high point for CHRS and MLECW.


Loading charts...

Drawdown Indicators


CHRSMLECWDifference

Max Drawdown

Largest peak-to-trough decline

-98.21%

-99.71%

+1.50%

Max Drawdown (1Y)

Largest decline over 1 year

-45.82%

-75.63%

+29.81%

Max Drawdown (3Y)

Largest decline over 3 years

-87.71%

-94.66%

+6.95%

Max Drawdown (5Y)

Largest decline over 5 years

-96.47%

Max Drawdown (10Y)

Largest decline over 10 years

-97.88%

Current Drawdown

Current decline from peak

-96.05%

-98.91%

+2.86%

Average Drawdown

Average peak-to-trough decline

-63.60%

-97.25%

+33.65%

Ulcer Index

Depth and duration of drawdowns from previous peaks

24.10%

47.34%

-23.24%

Volatility

CHRS vs. MLECW - Volatility Comparison

The current volatility for Coherus BioSciences, Inc. (CHRS) is 16.95%, while Moolec Science SA Warrant (MLECW) has a volatility of 43.15%. This indicates that CHRS experiences smaller price fluctuations and is considered to be less risky than MLECW based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CHRSMLECWDifference

Volatility (1M)

Calculated over the trailing 1-month period

16.95%

43.15%

-26.20%

Volatility (6M)

Calculated over the trailing 6-month period

59.73%

216.72%

-156.99%

Volatility (1Y)

Calculated over the trailing 1-year period

81.94%

289.68%

-207.74%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

84.83%

306.64%

-221.81%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

74.98%

306.64%

-231.66%

Dividends

CHRS vs. MLECW - Dividend Comparison

Neither CHRS nor MLECW has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

CHRS vs. MLECW - Financials Comparison

This section allows you to compare key financial metrics between Coherus BioSciences, Inc. and Moolec Science SA Warrant. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M100.00M20222023202420252026
12.31M
2.64M
(CHRS) Total Revenue
(MLECW) Total Revenue
Values in USD except per share items

Frequently Asked Questions


CHRS and MLECW have a correlation of -0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MLECW has higher volatility (43.15%) compared to CHRS (16.95%). In terms of maximum drawdown, CHRS dropped -98.21% vs MLECW's -99.71%.

CHRS currently has the higher Sharpe Ratio (1.21 vs 0.02), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CHRS and MLECW

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer